{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:50:00Z","timestamp":1782150600513,"version":"3.54.5"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Interstitial lung disease (ILD) can lead to pulmonary hypertension (PH), contributing to reduced exercise capacity in patients with ILD. Inhaled nitric oxide (iNO) reduces pulmonary artery pressure and pulmonary vascular resistance and may improve exercise capacity in this population; however, the available evidence remains limited. Therefore, we conducted a systematic review and meta-analysis to compare the efficacy and safety of iNO versus placebo in patients with ILD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, Cochrane databases, and ClinicalTrials.gov for randomized controlled trials (RCTs) comparing iNO with placebo in patients with ILD. The primary endpoint was 6-minute walk distance (6MWD). Secondary endpoint was moderate-to-vigorous physical activity (MVPA). Safety endpoint was any adverse events. Continuous endpoints were reported using mean differences (MDs) or standardized mean differences (SMDs), and binary endpoints were reported using risk ratios (RRs), all with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four RCTs, including one crossover trial, enrolling 274 patients were analyzed. Of these, 172 received iNO. The median follow-up period was 12 weeks. In the pooled analyses, iNO likely results in little to no difference in 6MWD compared with placebo (MD 1.83m; 95% CI \u221212.98 to 16.64; p\u2009=\u20090.81), and may result in little to no difference in any adverse events (RR 1.12; 95% CI 0.97 to 1.30; p\u2009=\u20090.12) and MVPA (SMD 0.32; 95% CI \u22120.93 to 1.56; p\u2009=\u20090.39).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>INO did not demonstrate improvements in 6MWD or MVPA. These findings do not support routine use of iNO in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0351862","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:25:49Z","timestamp":1782149149000},"page":"e0351862","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inhaled nitric oxide in fibrotic and advanced interstitial lung disease: A systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6871-8551","authenticated-orcid":true,"given":"Shun","family":"Nakahara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Fujiuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"issue":"10309","key":"pone.0351862.ref001","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/S0140-6736(21)01826-2","article-title":"Treatment of fibrotic interstitial lung disease: current approaches and future directions","volume":"398","author":"KA Johannson","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"pone.0351862.ref002","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline","volume":"192","author":"G Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"19","key":"pone.0351862.ref003","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1001\/jama.2024.3669","article-title":"Interstitial lung disease: a review","volume":"331","author":"TM Maher","year":"2024","journal-title":"JAMA"},{"key":"pone.0351862.ref004","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2024.8693","article-title":"Pamrevlumab for idiopathic pulmonary fibrosis: the ZEPHYRUS-1 randomized clinical trial","volume":"332","author":"G Raghu","year":"2024","journal-title":"JAMA"},{"issue":"11","key":"pone.0351862.ref005","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/S2213-2600(21)00165-X","article-title":"Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study","volume":"9","author":"SD Nathan","year":"2021","journal-title":"Lancet Respir Med"},{"key":"pone.0351862.ref006","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.chest.2020.02.016","article-title":"A randomized, double-blind, placebo-controlled study of pulsed, inhaled nitric oxide in subjects at risk of pulmonary hypertension associated with pulmonary fibrosis","volume":"158","author":"SD Nathan","year":"2020","journal-title":"Chest"},{"key":"pone.0351862.ref007","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bph.14512","article-title":"Inhaled nitric oxide: inhalation of NO","volume":"176","author":"B Yu","year":"2019","journal-title":"Br J Pharmacol"},{"issue":"25","key":"pone.0351862.ref008","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMra051884","article-title":"Inhaled nitric oxide therapy in adults","volume":"353","author":"MJD Griffiths","year":"2005","journal-title":"N Engl J Med"},{"issue":"7","key":"pone.0351862.ref009","article-title":"Inhaled nitric oxide for the postoperative management of pulmonary hypertension in infants and children with congenital heart disease","volume":"2014","author":"M Bizzarro","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"pone.0351862.ref010","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/00003246-200201000-00014","article-title":"Inhaled nitric oxide increases endothelin-1 levels: a potential cause of rebound pulmonary hypertension","volume":"30","author":"JM Pearl","year":"2002","journal-title":"Crit Care Med"},{"issue":"5","key":"pone.0351862.ref011","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1164\/ajrccm.161.5.9806138","article-title":"The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide","volume":"161","author":"J Christenson","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pone.0351862.ref012","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1513\/AnnalsATS.202107-864OC","article-title":"A phase-2 exploratory randomized controlled trial of INOpulse in patients with fibrotic interstitial lung disease requiring oxygen","volume":"19","author":"CS King","year":"2022","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"pone.0351862.ref013","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1513\/AnnalsATS.202406-662OC","article-title":"Inhaled nitric oxide in fibrotic lung disease: a randomized, double-blind, placebo-controlled trial","volume":"21","author":"SD Nathan","year":"2024","journal-title":"Ann Am Thorac Soc"},{"key":"pone.0351862.ref014","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024)","author":"JPT Higgins","year":"2024"},{"key":"pone.0351862.ref015","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"JAC Sterne","year":"2019","journal-title":"BMJ"},{"key":"pone.0351862.ref016","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081903","article-title":"Core GRADE 1: overview of the Core GRADE approach","volume":"389","author":"G Guyatt","year":"2025","journal-title":"BMJ"},{"key":"pone.0351862.ref017","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"JAC Sterne","year":"2011","journal-title":"BMJ"},{"issue":"6","key":"pone.0351862.ref018","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1177\/0962280216669183","article-title":"Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range","volume":"27","author":"D Luo","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"pone.0351862.ref019","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"X Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"pone.0351862.ref020","volume-title":"Statistical power analysis for the behavioral sciences","author":"J Cohen","year":"1988","edition":"2"},{"issue":"1","key":"pone.0351862.ref021","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1186\/s12890-024-03051-4","article-title":"The acute effect of inhaled nitric oxide on the exercise capacity of patients with advanced interstitial lung disease: a randomized controlled trial","volume":"24","author":"L Freidkin","year":"2024","journal-title":"BMC Pulm Med"},{"issue":"10354","key":"pone.0351862.ref022","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","article-title":"Interstitial lung diseases","volume":"400","author":"M Wijsenbeek","year":"2022","journal-title":"Lancet"},{"issue":"3","key":"pone.0351862.ref023","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1513\/AnnalsATS.202502-148OC","article-title":"Utility of inhaled nitric oxide vasoreactivity challenge in pulmonary hypertension associated with interstitial lung disease","volume":"23","author":"MS Chhabria","year":"2026","journal-title":"Ann Am Thorac Soc"},{"issue":"3","key":"pone.0351862.ref024","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1152\/japplphysiol.01104.2010","article-title":"Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis","volume":"110","author":"I Blanco","year":"2011","journal-title":"J Appl Physiol (1985)"},{"key":"pone.0351862.ref025","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1164\/rccm.201007-1179OC","article-title":"Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference","volume":"183","author":"RM du Bois","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"pone.0351862.ref026","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1007\/s00408-024-00748-5","article-title":"Percent predicted vs. absolute six-minute walk distance as predictors of lung transplant-free survival in fibrosing interstitial lung diseases","volume":"202","author":"U Zanini","year":"2024","journal-title":"Lung"},{"issue":"14","key":"pone.0351862.ref027","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"M Humbert","year":"2004","journal-title":"N Engl J Med"},{"issue":"10030","key":"pone.0351862.ref028","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1016\/S0140-6736(16)30245-8","article-title":"High-flow oxygen therapy and other inhaled therapies in intensive care units","volume":"387","author":"SD Levy","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"pone.0351862.ref029","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/toxsci\/59.1.5","article-title":"The toxicology of inhaled nitric oxide","volume":"59","author":"B Weinberger","year":"2001","journal-title":"Toxicol Sci"},{"key":"pone.0351862.ref030","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/j.1651-2227.2010.01854.x","article-title":"Methaemoglobinaemia risk factors with inhaled nitric oxide therapy in newborn infants: nitric oxide and methaemoglobinaemia risk for the newborn","author":"I Hamon","year":"2010","journal-title":"Acta Paediatr"},{"issue":"5","key":"pone.0351862.ref031","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1113\/JP280913","article-title":"Inhaled nitric oxide improves ventilatory efficiency and exercise capacity in patients with mild COPD: A randomized-control cross-over trial","volume":"599","author":"DB Phillips","year":"2021","journal-title":"J Physiol"},{"issue":"18","key":"pone.0351862.ref032","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.jacc.2010.05.046","article-title":"Medical and surgical treatment of acute right ventricular failure","volume":"56","author":"T Lahm","year":"2010","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"pone.0351862.ref033","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1378\/chest.14-2475","article-title":"Management of idiopathic pulmonary fibrosis in the elderly patient: addressing key questions","volume":"148","author":"KC Meyer","year":"2015","journal-title":"Chest"},{"issue":"3","key":"pone.0351862.ref034","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S2213-2600(18)30502-2","article-title":"Lung transplantation for idiopathic pulmonary fibrosis","volume":"7","author":"PM George","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"8","key":"pone.0351862.ref035","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S2352-4642(19)30117-8","article-title":"Children\u2019s interstitial and diffuse lung disease","volume":"3","author":"S Cunningham","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"issue":"179","key":"pone.0351862.ref036","doi-asserted-by":"crossref","first-page":"250062","DOI":"10.1183\/16000617.0062-2025","article-title":"Old and emerging therapies for childhood interstitial lung disease (chILD): a systematic review","volume":"35","author":"V Tonazzo","year":"2026","journal-title":"Eur Respir Rev"},{"issue":"9","key":"pone.0351862.ref037","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S2213-2600(23)00259-X","article-title":"Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management","volume":"11","author":"KM Olsson","year":"2023","journal-title":"Lancet Respir Med"},{"issue":"3","key":"pone.0351862.ref038","doi-asserted-by":"crossref","DOI":"10.1152\/ajpcell.00124.2023","article-title":"The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype","volume":"325","author":"YA Mebratu","year":"2023","journal-title":"Am J Physiol Cell Physiol"},{"issue":"2","key":"pone.0351862.ref039","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.mad.2009.12.010","article-title":"Alterations in the activity and expression of endothelial NO synthase in aged human endothelial cells","volume":"131","author":"HJ Yoon","year":"2010","journal-title":"Mech Ageing Dev"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T17:25:55Z","timestamp":1782149155000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0351862"}},"subtitle":[],"editor":[{"given":"Selvakumar","family":"Subbian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":39,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0351862","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]}}}